ASTRAZENECA AND ATHEROGENICS ANNOUNCE LATE STAGE LICENSING AND COMMERCIALISATION AGREEMENT FOR NOVEL ATHEROSCLEROSIS DRUG AGI-1067
AstraZeneca today announced that it has entered into a licensing deal with AtheroGenics, Inc. (Nasdaq: AGIX) for the global development and commercialisation of their anti-inflammatory cardiovascular product candidate, AGI-1067. AGI-1067 is an investigational oral drug for the treatment of atherosclerosis, the underlying disease process that leads to heart attacks and strokes and is currently in Phase III development in the ARISE (Aggressive Reduction of Inflammation Stops Events) trial. Under the terms of the agreement AtheroGenics will receive an upfront fee of $50 million and, subject to